Skip to main content

Table 1 Clinical manifestation for each patient at baseline a (n = 40)*

From: Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study

Patient/age (yr)

Disease duration (mo)

Baseline SLEDAI score

Baseline BILAG score

Total cumulative dose of IS

Clinical outcomes after MSCT

Clinical manifestations

1/46

40

17

12

CYC 0.8 gm/mo × 28 mo

PCR

LN, A, C, V, H, ANA+, anti-dsDNA+

2/37

41

12

12

CYC 0.8 gm/mo × 35 mo

PCR

A, LN, V, ANA+, anti-dsDNA+, H

3/21

50

11

9

MMF 1.5 gm/d × 31 mo

NR

V, LN, C, anti-SM+

4/28

98

9

9

CYC 0.8 gm/mo × 10 mo, CYC 0.8 gm/mo combined with MMF 1.0 gm/d × 28 mo (discontinue), LEF 20 mg/d × 31 mo

MCR

V, A, alopecia, LN, C, ANA+, anti-dsDNA+

5/26

120

12

8

MMF 2.0 gm/d × 50 mo (discontinue), CYC 0.8 gm/mo × 20 mo

NR

V, A, LN, ANA+, anti-dsDNA+

6/23

15

14

19

CYC 0.8 gm/mo × 15 mo, LEF 20 mg/d × 10 mo

NR

V, A, F, LN, P, ANA+, anti-dsDNA+

7/20

62

12

18

MMF 1.5 gm/d × 34 mo (discontinued), CYC 0.8 gm/mo × 24 mo

PCR

A, F, LN, C, P, ANA+

8/43

26

34

20

CYC 0.8 gm/mo × 10 mo (discontinued), LEF 20 mg/d × 10 mo

PCR → R

C, V, LN, A, seizures, ANA+

9/36

97

10

26

CYC 0.8 gm/mo × 29 mo

MCR → R

C, V, A, LN, P, ANA+

10/39

60

10

7

CYC 0.8 gm/mo × 25 mo (discontinued), LEF 20 mg/d × 30 mo

PCR

LN, A, V, ANA+, anti-SM+

11/22

40

8

16

CYC 0.8 gm/mo × 25 mo

NR

LN, C, P, ANA+, anti-dsDNA+

12/20

50

14

13

CYC 0.8 gm/mo × 15 mo (discontinued), VCR 1 mg/week × 4times (discontinued)

NR

A, severe thrombocytopenia, V, F, ANA+, anti-dsDNA+, anti-SM+

13/17

75

7

6

MMF 1.5 gm/d × 13 mo (discontinued), LEF 20 mg/d × 30 mo

NR

Severe thrombocytopenia, LN, A, ANA+, anti-dsDNA+

14/21

39

12

11

CYC 0.8 gm/mo × 17 mo

NR

LN, F, P, A, anti-dsDNA+

15/36

60

10

7

LEF 20 mg/d × 20 mo (discontinued), CYC 0.8 gm/mo × 37 mo

MCR

LN, V, P, A, ANA+, anti-SM+

16/16

49

11

15

CYC 0.8 gm/mo × 17 mo (discontinued), LEF 20 mg/d × 20 mo

NR

LN, A, V, ANA+

17/44

145

4

8

CYC 0.8 gm/mo × 64 mo

NR

LN, A, V, C, ANA+

18/44

85

8

9

CYC 0.8 gm/mo × 40 mo

PCR

A, LN, F, ANA+, anti-dsDNA+

19/29

86

10

5

CYC 0.8 gm/mo × 24 mo

PCR → R

LN, A, P, F, ANA+, anti-dsDNA+

20/54

264

8

4

CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 12  mo, then MMF 1.0 gm/d × 28 mo

MCR

LN, A, V, C, ANA+

21/36

121

13

13

CYC 0.8 gm/mo × 25 mo, LEF 20 mg/d × 40 mo

PCR → R

LN, A, V, C

22/40

24

12

8

CYC 0.8 gm/mo × 18 mo

NR

F, V, LN, C, ANA+

23/35

25

14

24

CYC 0.8 gm/mo × 21 mo

NR

F, A, V, LN, P

24/27

48

12

7

LEF 20 mg/d × 4 mo (discontinued), CYC 0.8 gm/mo × 40 mo

MCR

LN, F, A, P, ANA+, anti-SM+

25/30

102

10

7

MMF 2.0 gm/d × 6 mo, then tapered to 1.5 gm/d × 36 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 59 mo

PCR

V, A, LN, ANA+, anti-dsDNA+

26/31

62

8

3

MMF 1.5 gm/d × 8 mo, then tapered to 1.0 gm/d × 50 mo, LEF 20 mg/d × 19 mo

MCR → R

LN, V, P, ANA+, anti-dsDNA+

27/51

108

13

29

CYC 0.8 gm/mo × 41 mo, CsA 150 mg/d × 30 mo

NR

LN, V, A, C, seizures

28/50

110

10

11

LEF 20 mg/d × 39 mo (discontinued), CYC 0.8 gm/mo × 36 mo

MCR

A, V, LN, ANA+

29/45

102

10

9

CYC 1.2 gm/mo × 22 mo

NR

A, V, LN, ANA+, anti-dsDNA+

30/33

62

10

9

CYC 0.8 gm/mo × 21 mo, LEF 20 mg/d × 12 mo

MCR

LN, A, P, C

31/32

156

14

12

CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 6 mo, then tapered to 1.0 gm/d × 56 mo

MCR → R

LN, A, C, P

32/53

146

12

10

CYC 0.8 gm/mo × 24 mo, then tapered to 0.6 gm/mo × 42 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 40 mo

NR

LN, A, C, anti-dsDNA+

33/30

157

8

7

CYC 0.8 gm/mo × 16 mo (discontinued)

NR

V, LN, A, C, H

34/35

123

10

9

CYC 0.8 gm/mo × 18 mo, LEF 20 mg/d × 22 mo

NR

LN, A, H, C, ANA+

35/33

216

10

3

CYC 0.8 gm/mo × 26 mo

PCR

F, LN, V, C, A

36/39

99

5

7

CYC 0.8 gm/mo × 14 mo

MCR

LN, C, V, anti-dsDNA+

37/35

109

6

6

LEF 20 mg/d × 34 mo

PCR → R

LN, C, H, ANA+

38/31

160

9

7

LEF 20 mg/d × 13 mo (discontinued), CYC 0.8 gm/mo × 35 mo

MCR

LN, C, V, A

39/50

108

10

12

CYC 0.8 gm/mo × 14 mo

MCR

F, LN, A, V, C

40/35

96

8

8

CYC 0.8 gm/mo × 28 mo (discontinued), LEF 20 mg/d × 7 mo

MCR

LN, V, P, C, ANA+

  1. aA, Arthralgia; ANA, Antinuclear antibody; Anti-dsDNA, anti-double-stranded DNA antibody; C, Cytopenia; F, Febrile; H, Hypocomplementemia; IS, Immunosuppressive drug; LN, Lupus nephritis; MCR, Major clinical response; NR, Nonresponse; P, Polyserositis; PCR, Partial clinical response; R, Relapse; V, Vasculitis; VCR, Vincristine. Patients’ clinical manifestations were recorded within 1 week before umbilical cord mesenchymal stem cell transplantation. Total patient population = 40. Patients 1 to 26 were enrolled from the Department of Rheumatology, Affiliated Drum Tower Hospital, Nanjing University Medical School, Nanjing, China. Patients 27 to 32 were enrolled from the Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China. Patients 33 to 37 were enrolled from the Department of Rheumatology, Subei People’s Hospital of Jiangsu Province, Yangzhou, China. Patients 38 to 40 were enrolled from the Department of Rheumatology, Jiangsu Provincial People’s Hospital, Nanjing, China.